Pipeline & Science

IOA-244 is currently in Phase I/II clinical development in indications burdened by immune mediated resistance and a high intrinsic expression of PI3Kδ in both the cancer cells and in the tumor immune landscape.

The phosphatidylinositol 3-kinase (PI3K) signalling pathway is one of the most dysregulated pathways in cancer. We are developing a novel PI3Kδ inhibitor (IOA-244) with exquisite selectivity over PI3Kγ, translating into a new first in class mechanism in solid tumors and a class-leading safety and PK profile.

IOA-244 is an orally dosed molecule that modifies the balance of immune cells to harness a natural and sustained anti-tumor response.

IOA-289 has completed a Phase 1a healthy volunteer study and a Phase 1b study in pancreatic cancer is in planning - it is being developed as a first-in-class therapy for indications that over express ATX and are burdened with by stroma mediated resistance.

Autotaxin (ATX) is an extracellular enzyme that generates lysophosphatidic acid (LPA). LPA is a bioactive phospholipid that stimulates the proliferation, migration and survival of many cell types and has been implicated in a wide range of diseases, including cancer. We are developing a novel ATX inhibitor (IOA-289) with superior potency compared to clinical-stage ATX inhibitors.

IOA-289 is an orally dosed molecule that inhibits the growth and proliferation of cancer cells, stimulates immune cell infiltration into tumors and inhibits the development of fibrosis.

IOA-237 is in preclinical studies and is being developed as a combination therapy with IOA-244 and IOA-289 in indications burdened by stroma and immune mediated resistance.

CD73 is an enzyme that generates adenosine. Adenosine is a potent immunosuppressive factor contributing to tumor growth and survival. We are developing a selective CD73 monoclonal antibody (IOA-237) that has superior potency on cell surface and soluble CD73 compared to clinical stage competitors.

IOA-237 is a fully human mAb that disrupts CD73-mediated adenosine production. It is cross-reactive to mouse and human CD73, enabling a rapid development pathway.

IOA-244-101 is a Phase 1a/1b, open label, dose escalation and expansion multicentre study of IOA-244, an orally bioavailable, selective PI3Kδ inhibitor in patients with metastatic malignancies. This is a two-part first-in-human study in approximately 60 participants, where Part A is a dose-escalation study with IOA-244 and Part B is a dose-expansion in parallel cohorts, including malignancies of Uveal Melanoma, Cutaneous Melanoma, Mesothelioma, Myelofibrosis, Non-Hodgkin Lymphoma and NSCLC.

The completed dose-escalation phase (Part A) evaluated the safety and tolerability of IOA-244 as monotherapy and documented preliminary signs of clinical efficacy benefit of IOA-244 as single agent in solid tumors.

The ongoing dose-expansion phase (Part B) evaluates the safety and tolerability of IOA-244 as monotherapy at the biological effective dose and in combination with standard of care therapies, such as pemetrexed/cisplatin and immune checkpoint inhibitors. Preliminary signs of clinical efficacy including overall response rate [ORR], progression-free survival [PFS], duration of response [DOR] and overall survival [OS] will be evaluated.

Additional study information can be found on clinicaltrials.gov

IOA-289-101 was a randomized, double-blind, placebo-controlled, dose escalation study for the assessment of safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (SAD) of IOA-289, an orally bioavailable, selective ATX inhibitor in healthy volunteers. The trial successfully completed in December 2022 with no negative safety or tolerability signals.

Additional study information can be found on clinicaltrials.gov

The IOA-289-102 Phase 1 study will investigate the safety, tolerability and activity of IOA-289 at the biologically effective dose in approximately 24 patients with pancreatic cancer. It is currently in preparation.